Iterum Therapeutics Plc Stock In The News

ITRM Stock  USD 1.33  0.07  5.00%   
Our overall analysis of Iterum Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Iterum Therapeutics PLC. The specific impact of Iterum Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Iterum Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Iterum Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Iterum Therapeutics Backtesting and Iterum Therapeutics Hype Analysis.

Iterum Therapeutics Today Top News and Investor Outlook

Yahoo News
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ...
https://finance.yahoo.com/news/iterum-therapeutics-plc-itrm-q4-070641185.html
 Bullish
Macroaxis News: globenewswire.com
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
https://www.globenewswire.com/news-release/2025/02/07/3022699/0/en/Iterum-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html
 Bullish
Macroaxis News: globenewswire.com
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
https://www.globenewswire.com/news-release/2025/01/31/3018754/0/en/Iterum-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2024-Financial-Results-on-February-7-2025.html
 Neutral
Yahoo News
Ken Griffin Stock Portfolio: Top 10 Stock Picks
https://finance.yahoo.com/news/ken-griffin-stock-portfolio-top-144337203.html
 Bullish
Macroaxis News: globenewswire.com
Iterum Therapeutics Reports Third Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/11/14/2779916/0/en/Iterum-Therapeutics-Reports-Third-Quarter-2023-Financial-Results.html
 Neutral
Macroaxis News: globenewswire.com
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
https://www.globenewswire.com/news-release/2023/11/07/2775107/0/en/Iterum-Therapeutics-to-Provide-Business-Update-and-Report-Third-Quarter-2023-Financial-Results-on-November-14-2023.html
 Neutral
Macroaxis News: globenewswire.com
Iterum Therapeutics Announces Completion...
https://www.globenewswire.com/news-release/2023/10/24/2765569/0/en/Iterum-Therapeutics-Announces-Completion-of-Enrollment-in-its-REASSURE-Phase-3-Clinical-Trial-of-Oral-Sulopenem-in-Uncomplicated-Urinary-Tract-Infections.html
 Bullish
Macroaxis News: globenewswire.com
Iterum Therapeutics to Present Data at IDWeek 2023
https://www.globenewswire.com/news-release/2023/10/12/2759344/0/en/Iterum-Therapeutics-to-Present-Data-at-IDWeek-2023.html
 Neutral
Macroaxis News: globenewswire.com
Iterum Therapeutics Reports Second Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/08/11/2723446/0/en/Iterum-Therapeutics-Reports-Second-Quarter-2023-Financial-Results.html
 Neutral
Yahoo News
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
https://finance.yahoo.com/news/iterum-therapeutics-business-report-second-210000002.html
 Neutral

Iterum Therapeutics PLC Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Iterum and other traded companies coverage with news coverage. We help investors stay connected with Iterum headlines for the 3rd of March to make an informed investment decision based on correlating the impacts of news items on Iterum Stock performance. Please note that trading solely based on the Iterum Therapeutics PLC hype is not for everyone as timely availability and quick action are needed to avoid losses.
Iterum Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Iterum Therapeutics PLC investors visualize upcoming and past events in order to time the market based on Iterum Therapeutics PLC noise-free hype analysis.
Iterum Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Iterum earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Iterum Therapeutics that are available to investors today. That information is available publicly through Iterum media outlets and privately through word of mouth or via Iterum internal channels. However, regardless of the origin, that massive amount of Iterum data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Iterum Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Iterum Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Iterum Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Iterum Therapeutics alpha.

Iterum Largest EPS Surprises

Earnings surprises can significantly impact Iterum Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-14
2024-09-30-0.21-0.24-0.0314 
2025-02-07
2024-12-31-0.24-0.120.1250 
2024-08-09
2024-06-30-0.45-0.30.1533 
2023-08-11
2023-06-30-0.79-0.95-0.1620 
2024-05-13
2024-03-31-0.72-0.460.2636 
2022-03-28
2021-12-31-0.6-0.30.350 
View All Earnings Estimates

Iterum Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Iterum Therapeutics PLC Stock. Current markets are slightly bullish. About 58% of major world exchanges and indexes are currently up. See today's market update for more information.
Macroaxis News
21st of February 2025
Acquisition by Corey Fishman of 14333 shares of Iterum Therapeutics subject to Rule 16b-3
at MacroaxisInsider 
Gurufocus Stories at Macroaxis
7th of February 2025
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
at gurufocus.com 
Yahoo News
31st of January 2025
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Febru...
at finance.yahoo.com 
Macroaxis News
9th of December 2024
Disposition of 36798 shares by Dunne Michael W. of Iterum Therapeutics subject to Rule 16b...
at MacroaxisInsider 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Iterum Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Iterum Therapeutics' short interest history, or implied volatility extrapolated from Iterum Therapeutics options trading.
When determining whether Iterum Therapeutics PLC is a strong investment it is important to analyze Iterum Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iterum Therapeutics' future performance. For an informed investment choice regarding Iterum Stock, refer to the following important reports:
Check out Iterum Therapeutics Backtesting and Iterum Therapeutics Hype Analysis.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.26)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.33)
Return On Equity
(5.56)
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.